Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis
Dry eye disease (DED) is a multifactorial disease that causes ocular discomfort and visual impairment on a damaged ocular surface. Lifitegrast, a novel T-cell integrin antagonist, was approved in the United States in July 2016 as a 5% (50 mg/mL) ophthalmic solution for DED management. Currently, no...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/17/5014 |
| _version_ | 1797494797359906816 |
|---|---|
| author | Jing-Xing Li Yi-Yu Tsai Chun-Ting Lai You-Ling Li Ying-Hsuen Wu Chun-Chi Chiang |
| author_facet | Jing-Xing Li Yi-Yu Tsai Chun-Ting Lai You-Ling Li Ying-Hsuen Wu Chun-Chi Chiang |
| author_sort | Jing-Xing Li |
| collection | DOAJ |
| description | Dry eye disease (DED) is a multifactorial disease that causes ocular discomfort and visual impairment on a damaged ocular surface. Lifitegrast, a novel T-cell integrin antagonist, was approved in the United States in July 2016 as a 5% (50 mg/mL) ophthalmic solution for DED management. Currently, no meta-analysis and systemic review based on relevant studies have been conducted. This study aimed to evaluate the efficacy and safety of lifitegrast in patients with DED. We systematically searched Embase, Medline, PubMed, and Web of Science for randomized controlled trials (RCTs) and nonrandomized studies evaluating lifitegrast effects on symptomatic DED. Then, inferior corneal staining score, total corneal staining score (TCSS), nasal lissamine staining score (NLSS), total lissamine staining score, ocular discomfort score (ODS), eye discomfort score (visual analog scale (VAS) score), eye dryness score (EDS), ocular surface disease index score (OSDI-S), and tear break-up time (TBUT) were assessed. Clinical global impression and safety profiles were also evaluated. The studies were pooled in a random-effects model. We included five RCTs, one case–control study, and four longitudinal or retrospective studies, comprising 3197 participants. In the meta-analysis, lifitegrast was superior to the placebo because it improved TCSS, NLSS, TBUT, ODS, eye discomfort score, EDS, and OSDI-Sin DED. However, lifitegrast showed higher risks for ocular and non-ocular treatment-emergent adverse events (TEAEs) overall or at a mild or moderate level. Nonetheless, its incidence of adverse events slightly differed from that in the placebo, especially instillation site discomforts and dysgeusia, thereby considered safe and tolerable. Claims of withdrawal during follow-up caused by TEAEs were extremely rare. Lifitegrast improves DED, although dysgeusia, installation site pain, and irritation may be a concern for some. Overall, most of the adverse events are tolerable. Lifitegrast can alleviate refractory DED and improves patients’ quality of life. |
| first_indexed | 2024-03-10T01:39:27Z |
| format | Article |
| id | doaj.art-7a189301d68e4a55a011bc988c5b0bfb |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T01:39:27Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-7a189301d68e4a55a011bc988c5b0bfb2023-11-23T13:26:15ZengMDPI AGJournal of Clinical Medicine2077-03832022-08-011117501410.3390/jcm11175014Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-AnalysisJing-Xing Li0Yi-Yu Tsai1Chun-Ting Lai2You-Ling Li3Ying-Hsuen Wu4Chun-Chi Chiang5Department of General Medicine, China Medical University Hospital, Taichung 404327, TaiwanSchool of Medicine, China Medical University, Taichung 406040, TaiwanDepartment of Ophthalmology, China Medical University Hospital, China Medical University, Taichung 404327, TaiwanSchool of Medicine, China Medical University, Taichung 406040, TaiwanDepartment of Ophthalmology, China Medical University Hospital, China Medical University, Taichung 404327, TaiwanSchool of Medicine, China Medical University, Taichung 406040, TaiwanDry eye disease (DED) is a multifactorial disease that causes ocular discomfort and visual impairment on a damaged ocular surface. Lifitegrast, a novel T-cell integrin antagonist, was approved in the United States in July 2016 as a 5% (50 mg/mL) ophthalmic solution for DED management. Currently, no meta-analysis and systemic review based on relevant studies have been conducted. This study aimed to evaluate the efficacy and safety of lifitegrast in patients with DED. We systematically searched Embase, Medline, PubMed, and Web of Science for randomized controlled trials (RCTs) and nonrandomized studies evaluating lifitegrast effects on symptomatic DED. Then, inferior corneal staining score, total corneal staining score (TCSS), nasal lissamine staining score (NLSS), total lissamine staining score, ocular discomfort score (ODS), eye discomfort score (visual analog scale (VAS) score), eye dryness score (EDS), ocular surface disease index score (OSDI-S), and tear break-up time (TBUT) were assessed. Clinical global impression and safety profiles were also evaluated. The studies were pooled in a random-effects model. We included five RCTs, one case–control study, and four longitudinal or retrospective studies, comprising 3197 participants. In the meta-analysis, lifitegrast was superior to the placebo because it improved TCSS, NLSS, TBUT, ODS, eye discomfort score, EDS, and OSDI-Sin DED. However, lifitegrast showed higher risks for ocular and non-ocular treatment-emergent adverse events (TEAEs) overall or at a mild or moderate level. Nonetheless, its incidence of adverse events slightly differed from that in the placebo, especially instillation site discomforts and dysgeusia, thereby considered safe and tolerable. Claims of withdrawal during follow-up caused by TEAEs were extremely rare. Lifitegrast improves DED, although dysgeusia, installation site pain, and irritation may be a concern for some. Overall, most of the adverse events are tolerable. Lifitegrast can alleviate refractory DED and improves patients’ quality of life.https://www.mdpi.com/2077-0383/11/17/5014dry eye diseaseDEDlifitegrastlymphocyte function-associated antigen 1LFA-1Xiidra |
| spellingShingle | Jing-Xing Li Yi-Yu Tsai Chun-Ting Lai You-Ling Li Ying-Hsuen Wu Chun-Chi Chiang Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis Journal of Clinical Medicine dry eye disease DED lifitegrast lymphocyte function-associated antigen 1 LFA-1 Xiidra |
| title | Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis |
| title_full | Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis |
| title_fullStr | Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis |
| title_short | Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis |
| title_sort | lifitegrast ophthalmic solution 5 is a safe and efficient eyedrop for dry eye disease a systematic review and meta analysis |
| topic | dry eye disease DED lifitegrast lymphocyte function-associated antigen 1 LFA-1 Xiidra |
| url | https://www.mdpi.com/2077-0383/11/17/5014 |
| work_keys_str_mv | AT jingxingli lifitegrastophthalmicsolution5isasafeandefficienteyedropfordryeyediseaseasystematicreviewandmetaanalysis AT yiyutsai lifitegrastophthalmicsolution5isasafeandefficienteyedropfordryeyediseaseasystematicreviewandmetaanalysis AT chuntinglai lifitegrastophthalmicsolution5isasafeandefficienteyedropfordryeyediseaseasystematicreviewandmetaanalysis AT youlingli lifitegrastophthalmicsolution5isasafeandefficienteyedropfordryeyediseaseasystematicreviewandmetaanalysis AT yinghsuenwu lifitegrastophthalmicsolution5isasafeandefficienteyedropfordryeyediseaseasystematicreviewandmetaanalysis AT chunchichiang lifitegrastophthalmicsolution5isasafeandefficienteyedropfordryeyediseaseasystematicreviewandmetaanalysis |